Multiply deleted [E1, polymerase-, and pTP-] adenovirus vector persists despite deletion of the preterminal protein

Journal of Gene Medicine

Volumn 2, Issue 4, 2000, Pages 250-259

  Hodges, Bradley L ^a   Serra, Delila ^a   Hu, Huimin ^a   Begy, Catherine A ^b   Chamberlain, Jeffrey S ^b   Amalfitano, Andrea ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Adenovirus; Gene therapy; Polymerase; Preterminal

Indexed keywords

ADENOVIRIDAE;

DNA DIRECTED DNA POLYMERASE; PHOSPHOPROTEIN; PRETERMINAL PROTEIN, ADENOVIRUS; PROTEIN PRECURSOR; VIRUS PROTEIN;

ADENOVIRUS; ANIMAL; ARTICLE; C57BL MOUSE; CELL LINE; GENE DELETION; GENE TRANSFER; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; HELPER VIRUS; HUMAN; MOUSE; MOUSE MUTANT; VIRUS GENOME;

ADENOVIRIDAE; ADENOVIRUS E1 PROTEINS; ANIMALS; CELL LINE; DNA-DIRECTED DNA POLYMERASE; GENE DELETION; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; GENOME, VIRAL; HELPER VIRUSES; HUMANS; MICE; MICE, INBRED C57BL; MICE, SCID; PHOSPHOPROTEINS; PROTEIN PRECURSORS; TRANSDUCTION, GENETIC; VIRAL PROTEINS;

EID: 0034218917     PISSN: 1099498X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1521-2254(200007/08)2:4<250::AID-JGM113>3.0.CO;2-3     Document Type: Article

References (45)

1. Yang Y, Nunes FA, Berencsi K, Gonczol E, Engelhardt JF, Wilson JM. Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis. Nat Genet 1994; 7: 362-369.
2. Brough DE, Lizonova A, Hsu C, Kulesa VA, Kovesdi I. A gene transfer vector-cell line system for complete functional complementation of adenovirus early regions E1 and E4. J Virol 1996; 70: 6497-6501.
3. Wang Q, Jia XC, Finer MH. A packaging cell line for propagation of recombinant adenovirus vectors containing two lethal gene-region deletion. Gene Ther 1995; 2: 775-783.
4. Armentano D, Sookdeo CC, Hehir KM, et al. Characterization of an adenovirus gene transfer vector containing an E4 deletion. Hum Gene Ther 1995; 6: 1343-1353.
5. Gorziglia MI, Kadan MJ, Yei S, et al. Elimination of both E1 and E2a from adenovirus vectors further improves prospects for in vivo human gene therapy. J Virol 1996; 70: 4173-4178.
6. Amalfitano A, Chamberlain JS. Isolation and characterization of packaging cell lines that coexpress the adenovirus E1, DNA polymerase, and preterminal proteins - implications for gene therapy. Gene Ther 1997; 4: 258-263.
7. Hardy S, Kitamura M, Harrisstansil T, Dai YM, Phipps ML. Construction of adenovirus vectors through cre-lox recombination. J Virol 1997; 71: 1842-1849.
8. Parks RJ, Graham FL. A helper-dependent system for adenovirus vector production helps define a lower limit for efficient DNA packaging. J Virol 1997; 71: 3293-3298.
9. Mitani K, Graham FL, Caskey CT, Kochanek S. Rescue, propagation, and partial purification of a helper virus-dependent adenovirus vector. Proc Natl Acad Sci U S A 1995; 92: 3854-3858.
10. Kochanek S, Clemens PR, Mitani K, Chen HH, Chan S, Caskey CT. A new adenoviral vector - Replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase. Proc Natl Acad Sci U S A 1996; 93: 5731-5736.
11. Clemens PR, Kochanek S, Sunada Y, et al. In vivo muscle gene transfer of full-length dystrophin with an adenoviral vector that lacks all viral genes. Gene Ther 1996; 3: 965-972.
12. Chen HH, Mack LM, Kelly R, Ontell M, Kochanek S, Clemens PR. Persistence in muscle of an adenoviral vector that lacks all viral genes. Proc Natl Acad Sci U S A 1997; 94: 1645-1650.
13. Kumar-Singh R, Chamberlain JS. Encapsidated adenovirus minichromosomes allow delivery and expression of a 14 kb dystrophin cDNA to muscle cells. Hum Mol Genet 1996; 5: 913-921.
14. Lieber A, He CY, Kirillova I, Kay MA. Recombinant adenoviruses with large deletions generated by cre-mediated excision exhibit different biological properties compared with first-generation vectors in vitro and in vivo. J Virol 1996; 70: 8944-8960.
15. Parks RJ, Chen L, Anton M, Sankar U, Rudnicki MA, Graham FL. A helper-dependent adenovirus vector system - Removal of helper virus by cre-mediated excision of the viral packaging signal. Proc Natl Acad Sci U S A 1996; 93: 13565-13570.
16. Sandig V, Youil R, Bett A, et al. Optimization of the helper-dependent adenovirus system for production and potency in vivo. Proc Natl Acad Sci U S A 2000; 97: 1002-1007.
17. Lieber A, He CY, Kay MA. Adenoviral preterminal protein stabilizes mini-adenoviral genomes in vitro and in vivo. Nat Biotechnol 1997; 15: 1383-1387.
18. Zhou H, O'Neal W, Morral N, Beaudet AL. Development of a complementing cell line and a system for construction of adenovirus vectors with E1 and E2a deleted. J Virol 1996; 70[10]: 7030-7038.
19. Hu H, Serra D, Amalfitano A. Persistence of an [E1-, polymerase-] adenovirus vector despite transduction of a neoantigen into immune-competent mice. Hum Gene Ther 1999; 10: 355-364.
20. Gorziglia MI, Lapcevich C, Roy S, et al. Generation of an adenovirus vector lacking E1, E2a, E3, and all of E4 except open reading frame 3. J Virol 1999; 73: 6048-6055.
21. Gao GP, Yang YP, Wilson JM. Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy. J Virol 1996; 70: 8934-8943.
22. Dedieu JF, Vigne E, Torrent C, et al. Long-term gene delivery into the livers of immunocompetent mice with E1/E4-defective adenoviruses. J Virol 1997; 71: 4626-4637.
23. Wang Q, Greenburg G, Bunch D, Farson D, Finer MH. Persistent transgene expression in mouse liver following in vivo gene transfer with a delta-E1/delta-E4 adenovirus vector. Gene Ther 1997; 4: 393-400.
24. Amalfitano A, Begy CR, Chamberlain JS. Improved adenovirus packaging cell lines to support the growth of replication-defective gene-delivery vectors. Proc Natl Acad Sci U S A 1996; 93: 3352-3356.
25. Amalfitano A, Hauser MA, Hu H, Serra D, Begy CR, Chamberlain JS. Production and characterization of improved adenovirus vectors with the E1, E2b, and E3 genes deleted. J Virol 1998; 72: 926-933.
26. Hu HM, Serra D, Amalfitano A. Persistence of an [E1(-), polymeraseC-)] adenovirus vector despite transduction of a neoantigen into immune-competent mice. Hum Gene Ther 1999; 10: 355-364.
27. Loser P, Jennings GS, Strauss M, Sandig V. Reactivation of the previously silenced cytomegalovirus major immediate-early promoter in the mouse liver - involvement of NF-K-B. J Virol 1998; 72: 180-190.
28. Moorhead JW, Clayton GH, Smith RL, Schaack J. A replication-incompetent adenovirus vector with the preterminal protein gene deleted efficiently transduces mouse ears. J Virol 1999; 73: 1046-1053.
29. Svensson EC, Black HB, Dugger DL, et al. Long-term erythropoietin expression in rodents and non-human primates following intramuscular injection of a replication-defective adenoviral vector. Hum Gene Ther 1997; 8: 1797-1806.
30. Tripathy SK, Black HB, Goldwasser E, Leiden JM. Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors. Nat Med 1996; 2: 545-550.
31. Holt KH, Lim LE, Straub V, et al. Functional rescue of the sarcoglycan complex in the bio 14.6 Hamster using delta-sarcoglycan gene transfer. Mol Cell 1998; 1: 841-848.
32. Guo ZS, Wang LH, Eisensmith RC, Woo SL. Evaluation of promoter strength for hepatic gene expression in vivo following adenovirus-mediated gene transfer. Gene Ther 1996; 3: 802-810.
33. Kozarsky KF, Jooss K, Donahee M, Strauss JF, Wilson JM. Effective treatment of familial hypercholesterolaemia in the mouse model using adenovirus-mediated transfer of the VLDL receptor gene. Nat Genet 1996; 13: 54-62.
34. Michou AI, Santoro L, Christ M, Julliard V, Pavirani A, Mehtali M. Adenovirus-mediated gene transfer - Influence of transgene, mouse strain and type of immune response on persistence of transgene expression. Gene Ther 1997; 4: 473-482.
35. Scaria A, St George JA, Jiang C, Kaplan JM, Wadsworth SC, Gregory RJ. Adenovirus-mediated persistent cystic fibrosis transmembrane conductance regulator expression in mouse airway epithelium. J Virol 1998; 72: 7302-7309.
36. Barr D, Tubb J, Ferguson D, et al. Strain related variations in adenovirally mediated transgene expression from mouse hepatocytes in vivo: Comparisons between immunocompetent and immunodeficient inbred strains. Gene Ther 1995; 2: 151-155.
37. Yang Y, Li Q, Ertl HC, Wilson JM. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J Virol 1995; 69: 2004-2015.
38. Yang Y, Wilson JM. Clearance of adenovirus-infected hepatocytes by MHC class I-restricted CD4+ CTLs in vivo. J Immunol 1995; 155: 2564-2570.
39. Yang Y, Nunes FA, Berencsi K, Furth EE, Gonczol E, Wilson JM. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci U S A 1994; 91: 4407-4411.
40. Gilgenkrantz H, Duboc D, Juillard V, et al. Transient expression of genes transferred in vivo into heart using first-generation adenoviral vectors - Role of the immune response. Hum Gene Ther 1995; 6: 1265-1274.
41. Brough DE, Hsu C, Kulesa VA, et al. Activation of transgene expression by early region 4 is responsible for a high level of persistent transgene expression from adenovirus vectors in vivo. J Virol 1997; 71: 9206-9213.
42. Yang Y, Su Q, Wilson JM. Role of viral antigens in destructive cellular immune responses to adenovirus vector-transduced cells in mouse lungs. J Virol 1996; 70: 7209-7212.
43. Schiedner G, Morral N, Parks RJ, et al. Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. Nat Genet 1998; 18: 180-183.
44. Morsy MA, Gu MC, Motzel S, et al. An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene. Proc Nat Acad Sci U S A 1998; 95: 7866-7871.
45. Hartigan-O'Connor D, Amalfitano A, Chamberlain JS. Improved production of gutted adenovirus in cells expressing adenovirus preterminal protein and DNA polymerase. J Virol 1999; 73: 7835-7841.